Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001493152-22-020882
Filing Date
2022-08-01
Accepted
2022-08-01 16:10:33
Documents
1
Period of Report
2022-08-01

Document Format Files

Seq Description Document Type Size
1 ownership.html 3  
1 ownership.xml 3 4357
  Complete submission text file 0001493152-22-020882.txt   5821
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Issuer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
SIC: 2834 Pharmaceutical Preparations

Mailing Address 201 S. 25TH STREET APT. #521 PHILADELPHIA PA 19103
Business Address
Schmieg Martin E. (Reporting) CIK: 0001939388 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40101 | Film No.: 221124835